Roche partners with Zealand Pharma to push forward obesity drug

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The Swiss pharma giant and the Danish biotech will now work together to develop Zealand’s drug candidate petrelintide, aiming to test it on its own and in combination with Roche’s experimental CT-388.

The agreement includes additional payments based on certain clinical and sales goals being met, totaling up to $5.3 billion.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disorder

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 1, 2024

Canned Tuna Recall; Congressman Freezes During Floor Speech; Super Bowl ‘Flu’?

Note that some links may require registration or subscription. Canned tuna that was sold at Costco, Trader Joe’s, and H-E-B was recalled due to a

February 13, 2025

From drug shortages to high prices, U.S. system’s shortcomings have deep roots

American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.